SELLAS Life Sciences Group, Inc. SLS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $107.1M+49.2% | $71.79M+62.0% | $44.32M+75.2% | $25.3M-10.9% | $28.4M+105% | ||
| $111.17M+47.8% | $75.21M+53.3% | $49.05M+66.6% | $29.45M-7.9% | $31.97M+95.8% | ||
| $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | ||
| $114.18M+45.7% | $78.35M+52.0% | $51.56M+59.6% | $32.31M-7.6% | $34.96M+79.9% | ||
| $3.63M+23.2% | $2.95M+27.9% | $2.31M-30.9% | $3.34M-11.2% | $3.76M+7.3% | ||
| $6.46M-8.0% | $7.02M+18.4% | $5.93M-1.2% | $6M-12.9% | $6.89M-27.6% | ||
| $6.77M-9.5% | $7.47M+26.1% | $5.93M-3.8% | $6.16M-14.5% | $7.2M-27.8% | ||
| $18K+20.0% | $15K+25.0% | $12K+20.0% | $10K+11.1% | $9K+28.6% | ||
| -$283.4M-3.1% | -$274.99M-2.9% | -$267.33M-2.6% | -$260.54M-2.6% | -$253.94M-2.3% | ||
| $107.41M+51.6% | $70.87M+55.3% | $45.63M+74.5% | $26.15M-5.8% | $27.76M+193% | ||
| $114.18M+45.7% | $78.35M+52.0% | $51.56M+59.6% | $32.31M-7.6% | $34.96M+79.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are SELLAS Life Sciences Group, Inc.'s total assets?
- SELLAS Life Sciences Group, Inc. (SLS) holds $114.2M in total assets, up 226.6% year over year.
- How much debt does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc. carries $871.0K in total debt against $107.4M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc. holds $107.1M in cash and equivalents.
- Can SELLAS Life Sciences Group, Inc. cover its short-term obligations?
- Its current ratio is 17.22 — current assets exceed current liabilities.
- Where does SELLAS Life Sciences Group, Inc.'s balance sheet data come from?
- Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.